{"name": "Abraxis BioScience",
 "permalink": "abraxis-bioscience",
 "crunchbase_url": "http://www.crunchbase.com/company/abraxis-bioscience",
 "homepage_url": "http://www.abraxisbio.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2007,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "investorrelations@abraxisbio.com",
 "phone_number": "(310) 405-7522",
 "description": "",
 "created_at": "Thu Jul 01 01:43:16 UTC 2010",
 "updated_at": "Wed May 23 08:07:30 UTC 2012",
 "overview": "\u003Cp\u003EAbraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. \u003C/p\u003E\n\n\u003Cp\u003EThe company principally offers Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. \u003C/p\u003E\n\n\u003Cp\u003EIts other clinical product candidates include ABI-008, a phase II solvent-free and Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a phase I nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a phase II nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis. Abraxis BioScience has strategic relationships with Taiho Pharmaceutical Co., Ltd.; Biocon Limited; Green Cross Corporation; Specialised Therapeutics of Australia, Pty Ltd.; and ProMetic Life Sciences Inc. \u003C/p\u003E\n\n\u003Cp\u003EThe company was formerly known as New Abraxis, Inc. and changed its name to Abraxis BioScience, Inc. in November 2007. Abraxis BioScience, Inc. is based in Los Angeles, California.\u003C/p\u003E\n\n\u003Cp\u003EIn 2010, Abraxis BioScience was acquired by \u003Ca href=\"/company/celgene\" title=\"Celgene Corp\" rel=\"nofollow\"\u003ECelgene Corp\u003C/a\u003E.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[134,
       76],
      "assets/images/resized/0009/2195/92195v1-max-150x150.jpg"],
     [[134,
       76],
      "assets/images/resized/0009/2195/92195v1-max-250x250.jpg"],
     [[134,
       76],
      "assets/images/resized/0009/2195/92195v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Executive Chairman \u0026 CEO",
    "person":
     {"first_name": "Patrick",
      "last_name": "Soon-Shiong",
      "permalink": "patrick-soon-shiong",
      "image": null}},
   {"is_past": false,
    "title": "Senior Vice President Finance",
    "person":
     {"first_name": "Mitchell",
      "last_name": "Fogelman",
      "permalink": "mitchell-fogelman",
      "image": null}},
   {"is_past": true,
    "title": "Senior Vice President, Integrative Medicine and Translational Science",
    "person":
     {"first_name": "Lex",
      "last_name": "H.T. Van der Ploeg",
      "permalink": "lex-h-t-van-der-ploeg",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0027/2453/272453v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0027/2453/272453v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0027/2453/272453v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition":
  {"price_amount": 2900000000.0,
   "price_currency_code": "USD",
   "term_code": null,
   "source_url": "http://www.fiercebiotech.com/story/celgene-strikes-2-9b-deal-acquire-abraxis/2010-06-30?utm_medium=rss\u0026utm_source=rss",
   "source_description": "Celgene strikes $2.9B deal to acquire Abraxis",
   "acquired_year": 2010,
   "acquired_month": 6,
   "acquired_day": 30,
   "acquiring_company":
    {"name": "Celgene",
     "permalink": "celgene",
     "image":
      {"available_sizes":
        [[[113,
           99],
          "assets/images/resized/0006/8834/68834v1-max-150x150.png"],
         [[113,
           99],
          "assets/images/resized/0006/8834/68834v1-max-250x250.png"],
         [[113,
           99],
          "assets/images/resized/0006/8834/68834v1-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "11755 Wilshire Blvd.",
    "address2": "Suite 2000",
    "zip_code": "90025",
    "city": "Los Angeles",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        111],
       "assets/images/resized/0009/2194/92194v1-max-150x150.jpg"],
      [[250,
        185],
       "assets/images/resized/0009/2194/92194v1-max-250x250.jpg"],
      [[450,
        333],
       "assets/images/resized/0009/2194/92194v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}